Novavax Inc. (NASDAQ:NVAX)’s share price traded up 3.3% on Monday . The company traded as high as $7.97 and last traded at $7.87, with a volume of 3,033,058 shares traded. The stock had previously closed at $7.62.

A number of equities analysts recently weighed in on the stock. Vetr upgraded shares of Novavax from a “buy” rating to a “strong-buy” rating and set a $8.22 price objective for the company in a report on Tuesday, July 5th. Piper Jaffray Cos. restated an “overweight” rating and issued a $14.00 price objective on shares of Novavax in a report on Wednesday, June 29th. Zacks Investment Research upgraded shares of Novavax from a “sell” rating to a “hold” rating in a report on Friday, June 10th. Wedbush restated an “outperform” rating and issued a $14.00 price objective on shares of Novavax in a report on Thursday, June 2nd. Finally, Chardan Capital restated a “neutral” rating on shares of Novavax in a report on Monday, May 2nd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $12.19.

The stock’s 50 day moving average price is $6.55 and its 200 day moving average price is $5.77. The firm’s market capitalization is $2.10 billion.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by $0.02. The firm had revenue of $4.20 million for the quarter, compared to analysts’ expectations of $10.39 million. The business’s quarterly revenue was down 57.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.10) EPS. On average, analysts forecast that Novavax Inc. will post ($0.96) earnings per share for the current year.

In other Novavax news, Director Gary C. Evans sold 18,998 shares of the firm’s stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $6.50, for a total value of $123,487.00. Following the completion of the sale, the director now directly owns 321,979 shares in the company, valued at $2,092,863.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Gary C. Evans sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $5.41, for a total transaction of $270,500.00. Following the completion of the sale, the director now owns 357,111 shares of the company’s stock, valued at $1,931,970.51. The disclosure for this sale can be found here.

A number of large investors have recently made changes to their positions in the stock. ProShare Advisors LLC increased its stake in shares of Novavax by 10.4% in the fourth quarter. ProShare Advisors LLC now owns 266,138 shares of the biopharmaceutical company’s stock valued at $2,233,000 after buying an additional 25,114 shares during the period. Rhumbline Advisers increased its stake in shares of Novavax by 12.6% in the fourth quarter. Rhumbline Advisers now owns 271,881 shares of the biopharmaceutical company’s stock valued at $2,281,000 after buying an additional 30,395 shares during the period. American Century Companies Inc. increased its stake in shares of Novavax by 21.8% in the fourth quarter. American Century Companies Inc. now owns 354,286 shares of the biopharmaceutical company’s stock valued at $2,972,000 after buying an additional 63,306 shares during the period. Tekla Capital Management LLC purchased a new stake in shares of Novavax during the fourth quarter valued at $3,004,000. Finally, California State Teachers Retirement System increased its stake in shares of Novavax by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 496,682 shares of the biopharmaceutical company’s stock valued at $4,167,000 after buying an additional 7,860 shares during the period.

Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.